Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
(NasdaqGM:RYTM), — Q4 2025 preliminary net product revenues from global sales of IMCIVREE(R) (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 — — FY 2025 preliminary net product revenue of approximately $194 million, approximately 50% increase from FY2024 — — March 20, 2026 PDUFA goal date […]